Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma-Reference-Cited by-同舟云学术

Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma

Published:2024-01 Issue:1 Volume:19 Page:166-172
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Tagliamento Marco^ORCID,Di Maio Massimo,Remon Jordi,Bironzo Paolo,Genova Carlo,Facchinetti Francesco,Aldea Mihaela,Le Péchoux Cécile,Novello Silvia,Barlesi Fabrice,Besse Benjamin,Planchard David

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Mesothelioma: scientific clues for prevention, diagnosis, and therapy;Carbone;CA Cancer J Clin,2019

2. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet,2016

3. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma;Tagliamento;Crit Rev Oncol Hematol,2022

4. Immunotherapy for mesothelioma: moving beyond single immune check point inhibition;Cantini;Lung Cancer,2022

5. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report;Journal of Personalized Medicine;2024-04-08

2. Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma;Journal of Thoracic Oncology;2024-04

3. EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers;npj Precision Oncology;2024-02-16